Breaking

OpenAI Researcher Miles Wang in Talks to Launch AI Drug-Discovery Startup at $2B Valuation

July 14, 2026 at 20:30 EDT

Funding & M&A
Healthcare
Research & Papers

OpenAI researcher Miles Wang is in advanced talks to leave the company and found a startup that uses artificial intelligence for drug discovery, with early financing discussions valuing the venture at roughly $2 billion, according to reporting on the plans.

AI Talent · Drug Discovery

OpenAI Researcher in Talks to Launch $2B AI Drug-Discovery Startup

Miles Wang, of OpenAI's reinforcement-learning team, is said to be preparing a company built around AI-driven drug repurposing — an early round of roughly $200M would value the still-unformed venture at about $2 billion.

~$2B

Discussed valuation for the new venture

~$200M

Financing round being led by Lightspeed

Products, benchmarks or use cases so far

Capital Flowing Into AI Drug Discovery

Valuations, to scale ($ billions)

$2.0B

Wang venture
(discussed)

$2.1B

Isomorphic Labs
(Series B)

$3.8B

Chai Discovery
(valuation)

The Bet: Drug Repurposing

Existing / shelved drug

→

AI finds new therapeutic use

→

Existing safety data shortens path

The Enthusiasm

Better molecular prediction
End-to-end research platforms
Belief AI can compress dev timelines

The Hurdles

Data quality questions
Regulatory navigation
Thin record of predictions becoming approved drugs

For now, the venture exists chiefly as a set of negotiations and an ambition.

Wang has disputed elements of the fundraising figures and business description without offering alternatives. The technology remains unbuilt and unproven — a fresh test of whether tools honed on language and reasoning can deliver in medicine.

Continue reading

The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.